MedPath

Tipifarnib

Generic Name
Tipifarnib
Drug Type
Small Molecule
Chemical Formula
C27H22Cl2N4O
CAS Number
192185-72-1
Unique Ingredient Identifier
MAT637500A

Overview

Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication

Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/08/07
Phase 2
Recruiting
Giselle Sholler
2023/01/20
Phase 1
Withdrawn
2021/08/10
Phase 1
Active, not recruiting
2021/04/29
Phase 1
Terminated
2021/03/22
N/A
AVAILABLE
2020/02/26
Phase 2
Active, not recruiting
2018/10/25
Phase 2
Completed
2018/04/12
Phase 2
Terminated
Spanish Lung Cancer Group
2017/05/16
Phase 2
Active, not recruiting
2016/06/21
Phase 2
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.